Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Total Current Assets
All assets expected to be converted to cash or used up within one year.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets falls 39.5% from a year ago
Total current assets stood at $93.58M at the end of Q1 FY2026, down 39.5% from a year earlier and down 16.4% from the prior quarter. Over 3 fiscal years it compounded at +89.3% a year.
Context
- Total current assets amounted to 94.9% of total assets at the end of Q1 FY2026, down 3.5 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps falling in the next quarterly balance sheet after a -39.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 111.89M USD
- Year-over-year change
- +50.9%
- 3-year CAGR
- +89.3%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 111.89M | +50.9% |
| FY2024 | 2024-12-31 | 74.14M | +615.1% |
| FY2023 | 2023-12-31 | 10.37M | -37.1% |
| FY2022 | 2022-12-31 | 16.49M | — |
Total Current Assets vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's Mar 2026 total current assets of $93.58M is the 9th highest of the 11 companies compared; the peer median is $132.49M.
- Its year-over-year change of -39.5% is the 9th highest of 11, against a peer median of -21.6%.
- Total current assets amounts to 94.9% of total assets for AARD, versus a peer median of 83.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $232.61M | +143.5% | +37.9% | 98.8% | |
ZURAZura Bio Limited | Mar 2026 | $227M | +32.2% | +298.4% | 99.3% |
| Mar 2026 | $188.06M | -16.6% | -22.6% | 84.6% | |
| Mar 2026 | $178.41M | -26.5% | -13.1% | 56.7% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $142.59M | +398.5% | +50.1% | 97.8% |
| Mar 2026 | $122.38M | -43.7% | -17.7% | 82.1% | |
| Mar 2026 | $98.83M | -30.2% | -17.3% | 55.6% | |
| Mar 2026 | $96.56M | +2.2% | -18.3% | 71.5% | |
| Mar 2026 | $93.58M | -39.5% | +89.3% | 94.9% | |
| Mar 2026 | $88.83M | -30.0% | +85.8% | 88.9% | |
| Mar 2026 | $45.57M | -59.3% | -27.2% | 70.9% | |
| Peer median (excluding AARD) | $132.49M | -21.6% | -15.2% | 83.4% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.